JP6196224B2 - シアル酸類似体 - Google Patents

シアル酸類似体 Download PDF

Info

Publication number
JP6196224B2
JP6196224B2 JP2014537380A JP2014537380A JP6196224B2 JP 6196224 B2 JP6196224 B2 JP 6196224B2 JP 2014537380 A JP2014537380 A JP 2014537380A JP 2014537380 A JP2014537380 A JP 2014537380A JP 6196224 B2 JP6196224 B2 JP 6196224B2
Authority
JP
Japan
Prior art keywords
compound
group
structural formula
hydrogen
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014537380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530882A (ja
JP2014530882A5 (enExample
Inventor
エミル カッキス,
エミル カッキス,
スティーブン ジャングルズ,
スティーブン ジャングルズ,
ヘ ジャオ,
ヘ ジャオ,
Original Assignee
ウルトラジェニックス ファーマシューティカル インコーポレイテッド
ウルトラジェニックス ファーマシューティカル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウルトラジェニックス ファーマシューティカル インコーポレイテッド, ウルトラジェニックス ファーマシューティカル インコーポレイテッド filed Critical ウルトラジェニックス ファーマシューティカル インコーポレイテッド
Publication of JP2014530882A publication Critical patent/JP2014530882A/ja
Publication of JP2014530882A5 publication Critical patent/JP2014530882A5/ja
Application granted granted Critical
Publication of JP6196224B2 publication Critical patent/JP6196224B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02Acyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02Acyclic radicals
    • C07H7/027Keto-aldonic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2014537380A 2011-10-24 2012-10-24 シアル酸類似体 Active JP6196224B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550610P 2011-10-24 2011-10-24
US61/550,610 2011-10-24
PCT/US2012/061737 WO2013063149A1 (en) 2011-10-24 2012-10-24 Sialic acid analogs

Publications (3)

Publication Number Publication Date
JP2014530882A JP2014530882A (ja) 2014-11-20
JP2014530882A5 JP2014530882A5 (enExample) 2015-09-10
JP6196224B2 true JP6196224B2 (ja) 2017-09-13

Family

ID=48168447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537380A Active JP6196224B2 (ja) 2011-10-24 2012-10-24 シアル酸類似体

Country Status (13)

Country Link
US (5) US8840926B2 (enExample)
EP (1) EP2771348B1 (enExample)
JP (1) JP6196224B2 (enExample)
KR (1) KR102049214B1 (enExample)
CN (1) CN103974965B (enExample)
AU (1) AU2012328874B2 (enExample)
BR (1) BR112014009760B1 (enExample)
CA (1) CA2849114C (enExample)
ES (1) ES2807890T3 (enExample)
HK (1) HK1201067A1 (enExample)
IL (1) IL231714B (enExample)
MX (1) MX347541B (enExample)
WO (1) WO2013063149A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
BR112013000776A2 (pt) 2010-07-13 2016-05-24 Ultragenyx Pharmaceutical Inc método e formulação para tratamento de deficiência de ácido siálico
WO2013063149A1 (en) 2011-10-24 2013-05-02 Ultragenyx Pharmaceutical, Inc. Sialic acid analogs
CN104271125A (zh) * 2012-01-18 2015-01-07 奥特吉尼克斯制药公司 用于治疗唾液酸缺乏的方法和制剂
WO2017048817A1 (en) 2015-09-14 2017-03-23 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof
CN121079430A (zh) * 2023-02-17 2025-12-05 奥特吉尼克斯制药公司 唾液酸衍生物的结晶形式及其使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6168418A (ja) 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
JPS63139193A (ja) * 1986-11-28 1988-06-10 Mect Corp シアル酸誘導体1,7−ラクトン
US6156544A (en) 1993-06-09 2000-12-05 Glaxo Group Limited Process for the preparation of N-acetylneuraminic acid
CA2215978A1 (en) 1995-04-04 1996-10-10 Wound Healing Of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
WO1999052931A1 (fr) 1998-04-10 1999-10-21 Mitsubishi Chemical Corporation Dispersion solide contenant un derive d'acide sialique
KR20030006721A (ko) 2001-07-14 2003-01-23 삼성전자 주식회사 리소그라피 시스템 및 이를 이용한 레티클 표면의 파티클제거방법
BR0311978A (pt) 2002-06-21 2005-03-22 Novo Nordisk Healthcare Ag Preparação, método para preparar a mesma, formulação farmacêutica, métodos para tratar de uma sìndrome responsiva ao fator vii, para prevenir hemorragias indesejáveis, para prevenir coagulação sanguìnea indesejável e para prevenir as reações mediadas pelo fator tecidual, e, uso de uma preparação
US7238677B2 (en) 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
AU2004296404A1 (en) * 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
KR101202607B1 (ko) 2005-03-03 2012-11-20 마나테크 인코포레이티드 영양 보조제의 조절된 방출을 위한 방법 및 조성물
WO2007103286A2 (en) * 2006-03-02 2007-09-13 Spherics, Inc. Rate-controlled bioadhesive oral dosage formulations
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
WO2008150477A2 (en) 2007-05-31 2008-12-11 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine as a therapeutic agent
CA2698108A1 (en) 2007-08-27 2009-03-12 Massachusetts Institute Of Technology Bi-functional polymer-attached inhibitors of influenza virus
WO2009137827A2 (en) 2008-05-09 2009-11-12 Tiara Pharmaceuticals, Inc. Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
KR101116864B1 (ko) 2008-08-01 2012-02-29 주식회사 베네비오 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
US20100160363A1 (en) 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20100159001A1 (en) 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
JP5626734B2 (ja) * 2009-05-15 2014-11-19 公益財団法人ヒューマンサイエンス振興財団 Gneタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物
BR112013000776A2 (pt) 2010-07-13 2016-05-24 Ultragenyx Pharmaceutical Inc método e formulação para tratamento de deficiência de ácido siálico
WO2013063149A1 (en) 2011-10-24 2013-05-02 Ultragenyx Pharmaceutical, Inc. Sialic acid analogs
CN104271125A (zh) 2012-01-18 2015-01-07 奥特吉尼克斯制药公司 用于治疗唾液酸缺乏的方法和制剂
EP3252065B1 (en) 2015-01-28 2020-01-08 Kyowa Hakko Bio Co., Ltd. Crystal of ammonium n-acetylneuraminate anhydrate, and process for producing same
WO2017048817A1 (en) 2015-09-14 2017-03-23 Ultragenyx Pharmaceutical Inc. Crystal forms of sialic acid or salt or solvate thereof

Also Published As

Publication number Publication date
US20160297846A1 (en) 2016-10-13
AU2012328874B2 (en) 2017-08-31
US20200131215A1 (en) 2020-04-30
MX347541B (es) 2017-04-28
BR112014009760A2 (pt) 2017-04-18
US8840926B2 (en) 2014-09-23
JP2014530882A (ja) 2014-11-20
EP2771348A1 (en) 2014-09-03
MX2014004928A (es) 2014-11-10
KR102049214B1 (ko) 2019-11-28
US9221858B2 (en) 2015-12-29
CA2849114C (en) 2020-12-15
US20130122094A1 (en) 2013-05-16
CN103974965A (zh) 2014-08-06
WO2013063149A1 (en) 2013-05-02
CA2849114A1 (en) 2013-05-02
US20150038693A1 (en) 2015-02-05
KR20140084277A (ko) 2014-07-04
US10889607B2 (en) 2021-01-12
ES2807890T3 (es) 2021-02-24
US10457701B2 (en) 2019-10-29
AU2012328874A1 (en) 2014-04-10
BR112014009760B1 (pt) 2022-11-29
CN103974965B (zh) 2019-09-24
EP2771348A4 (en) 2015-09-09
BR112014009760A8 (pt) 2018-01-16
IL231714B (en) 2018-10-31
IL231714A0 (en) 2014-05-28
US20190127409A1 (en) 2019-05-02
US10065981B2 (en) 2018-09-04
EP2771348B1 (en) 2020-05-20
HK1201067A1 (en) 2015-08-21

Similar Documents

Publication Publication Date Title
US10889607B2 (en) Sialic acid analogs
JP6857124B2 (ja) Fxr/tgr5アゴニストとしての胆汁酸誘導体およびその使用方法
JP6065052B2 (ja) テトラヒドロカルボリン誘導体
AU2019351494B2 (en) Nitroxoline prodrug and use thereof
WO2014198195A1 (zh) 联芳基取代的4-氨基丁酸衍生物及其制备方法和用途
JP7057783B2 (ja) スルホニル尿素胆汁酸誘導体の調製方法
EP4361145A1 (en) Glp-1 receptor agonist and composition and use thereof
WO2008016006A1 (fr) Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
TW202233591A (zh) 2-吡啶酮及其使用方法
EP3904357A1 (en) Spiro compound and medical uses thereof
JP2012522796A (ja) プロスタグランジンeレセプター拮抗薬
EP4163287A1 (en) A class of aryl glucoside derivatives, preparation method therefor and application thereof
RS67310B1 (sr) Derivat aril glukozida i njegova upotreba u leku
US11565999B2 (en) Methods of synthesizing aztreonam derivatives
EP4166547A1 (en) Aryl glucoside derivative
HK40055242A (zh) 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
JP2021161092A (ja) 新規cdp−リビトール誘導体
TW202130619A (zh) 硝羥喹啉前藥及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170817

R150 Certificate of patent or registration of utility model

Ref document number: 6196224

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D03

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250